259 related articles for article (PubMed ID: 15548159)
21. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
22. Retrieval of zona-free immature oocytes in a woman with recurrent empty follicle syndrome: a case report.
Duru NK; Cincik M; Dede M; Hasimi A; Baser I
J Reprod Med; 2007 Sep; 52(9):858-63. PubMed ID: 17939607
[TBL] [Abstract][Full Text] [Related]
23. Selection of first in vitro fertilization cycle stimulation protocol for good prognosis patients: gonadotropin releasing hormone antagonist versus agonist protocols.
Johnston-MacAnanny EB; DiLuigi AJ; Engmann LL; Maier DB; Benadiva CA; Nulsen JC
J Reprod Med; 2011; 56(1-2):12-6. PubMed ID: 21366121
[TBL] [Abstract][Full Text] [Related]
24. GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Engmann L; Benadiva C
Hum Reprod; 2005 Nov; 20(11):3258-60; author reply 3260. PubMed ID: 16246862
[No Abstract] [Full Text] [Related]
25. Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol--a randomized study.
Lin YH; Hwang JL; Seow KM; Huang LW; Hsieh BC; Tzeng CR
Gynecol Endocrinol; 2006 Jun; 22(6):297-302. PubMed ID: 16785154
[TBL] [Abstract][Full Text] [Related]
26. Controlled ovarian hyperstimulation for in vitro fertilization using buserelin and gonadotropin in patients with previous failed cycles.
Loong EP; Tam PP; Chiu TT; Chan MY; Panesar NS; Lau J
Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):297-300. PubMed ID: 2129187
[TBL] [Abstract][Full Text] [Related]
27. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
29. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
[TBL] [Abstract][Full Text] [Related]
30. Endometrial thickness is related to miscarriage rate, but not to the estradiol concentration, in cycles down-regulated with gonadotropin-releasing hormone antagonist.
Detti L; Yelian FD; Kruger ML; Diamond MP; Rode A; Mitwally MF; Puscheck EE
Fertil Steril; 2008 Apr; 89(4):998-1001. PubMed ID: 17678904
[TBL] [Abstract][Full Text] [Related]
31. Can FSH co-trigger prevent OHSS?
Rosen MP; Meldrum DR
Fertil Steril; 2012 Mar; 97(3):534-5. PubMed ID: 22285746
[TBL] [Abstract][Full Text] [Related]
32. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
[TBL] [Abstract][Full Text] [Related]
33. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
34. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection.
Kim CH; Jeon GH; Cheon YP; Jeon I; Kim SH; Chae HD; Kang BM
Fertil Steril; 2009 Nov; 92(5):1758-60. PubMed ID: 19523618
[TBL] [Abstract][Full Text] [Related]
35. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Hudson C
Fertil Steril; 2011 Jun; 95(8):2715-7. PubMed ID: 21550042
[TBL] [Abstract][Full Text] [Related]
36. Agonist or antagonist: what is preferable for in vitro fertilization?
Ben-Rafael Z
Gynecol Endocrinol; 2012 Mar; 28 Suppl 1():18-21. PubMed ID: 22394299
[No Abstract] [Full Text] [Related]
37. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
[TBL] [Abstract][Full Text] [Related]
38. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
Elgindy EA; El-Haieg DO; El-Sebaey A
Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
[TBL] [Abstract][Full Text] [Related]
39. Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?
Orvieto R; Rabinson J; Meltcer S; Gemer O; Anteby EY; Zohav E
Fertil Steril; 2008 Mar; 89(3):736-7. PubMed ID: 17498708
[TBL] [Abstract][Full Text] [Related]
40. Luteal support post GnRH agonist trigger: do not stop too soon.
Kol S
Hum Reprod; 2005 Nov; 20(11):3257; author reply 3257-8. PubMed ID: 16246861
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
